Pharmaceutical groups Boehringer Ingelheim and Shire as well as Japanese conglomerate Mitsui’s corporate venturing unit and ATMI have helped Université Catholique de Louvain’s liver treatment spin out Promethera Biosciences raise €17m ($22.7m).

The companies were joined in the series B round for the Belgium-based cell therapy company, on Wednesday, by Belgium-based venture capital firm SambrInvest.

The Walloon Region, which has backed the company since it was founded, has also provided a loan of €6.6m to support its clinical development for…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?